Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCM-Support: Autologous Stem Cells and G-CSF for Dilated Cardiomyopathy
NCT03572660Phase 2Active, not recruiting
- Sponsor
- Barts Health NHS Trust
- Start
- Dec 2018
- Primary completion
- Mar 2030
- Modality
- Cytokines & Interferons, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mononuclear cells and filgrastim in dilated cardiomyopathy (DCM), sponsored by Barts Health NHS Trust. Primary endpoint: Left Ventricular Ejection Fraction at 3 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
autologous bone marrow derived mononuclear cellsfilgrastim
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT03572660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572660.